Organization
Cellectar Biosciences
4 clinical trials
Clinical trial
An Open-Label, Multicenter, Phase 2 Study of Iopofosine I 131 (CLR 131) in Patients With Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients With Waldenstrom Macroglobulinemia (CLOVER-WaM)Status: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
An Open-Label, Dose Escalation, Efficacy, and Safety Study of CLR 131 in Children, Adolescents, and Young Adults With Select Solid Tumors, Lymphoma, and Malignant Brain TumorsStatus: Active (not recruiting), Estimated PCD: 2022-09-25
Clinical trial
A Phase 1b, Open-Label, Study of a Novel Targeted Radiotherapy in Children, Adolescents and Young Adults With Inoperable Relapsed or Refractory High-Grade GliomaStatus: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple MyelomaStatus: Completed, Estimated PCD: 2020-12-09